NasdaqGM:HROWPharmaceuticals
Is Harrow’s (HROW) Reaffirmed 2025 Guidance Quietly Redefining Its Ophthalmic Growth Strategy?
Harrow, Inc. recently promoted Patrick W. Sullivan to Chief Commercial Officer and reaffirmed its full-year 2025 revenue guidance of US$270 million to US$280 million, underscoring continuity in its commercial leadership and financial outlook.
The combination of Sullivan’s long-standing commercial experience across major pharmaceutical companies and Harrow’s confirmed revenue targets highlights the company’s focus on execution in its ophthalmic portfolio.
We’ll now look at how Harrow’s...